Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VS-5584 (SB2343) is a pan-PI3K/mTOR kinase inhibitor.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 34.00 | |
2 mg | In stock | $ 48.00 | |
5 mg | In stock | $ 77.00 | |
10 mg | In stock | $ 101.00 | |
25 mg | In stock | $ 181.00 | |
50 mg | In stock | $ 328.00 | |
100 mg | In stock | $ 531.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 84.00 |
Description | VS-5584 (SB2343) is a pan-PI3K/mTOR kinase inhibitor. |
Targets&IC50 | mTOR:3.4 nM, PI3Kγ:3.0 nM, PI3Kα:2.6 nM, PI3Kβ:21 nM, PI3Kδ:2.7 nM |
In vitro | VS-5584 is an ATP-competitive inhibitor which selectively inhibits PI3K/mTOR signaling with equivalent low nanomolar potency against all human Class I PI3K isoforms and mTOR kinase. VS-5584 is approximately 10-fold selective for cancer stem cells with an EC50 of 15 nM in HMLE breast cancer cells. VS-5584 preferentially decreases CD44Hi/CD24Lo cells in an HMLER immortalized mammary cancer cell line. In SUM159 cells, VS-5584 effectively eliminates the cancer stem cell side population. [1] A large human cancer cell line panel screen (436 lines) reveals broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment. In the FLT3-ITD harboring MV4-11 cells, VS-5584 blocks pAkt (S473) and pAkt (T308) with IC50 of 12 and 13 nM, respectively. The IC50 of VS-5584 for pS6 (S240/244), pAkt (S473), and pAkt (T308) are 20, 23, and 15 nM, respectively. [2] |
In vivo | In mice bearing triple negative breast cancer tumors, oral dosing of VS-5584 decreases tumor cancer stem cells and induces tumor regression in taxane-resistant models. [1] In a PTENnull human prostate PC3 xenograft model, treatment with VS-5584 leads to significant tumor growth inhibition (TGI) of 79% and 113% for 11 and 25 mg/kg, respectively. In a FLT3-ITD AML xenograft model, VS-5584 treatment induces dose-dependent inhibition of tumor growth (28% for 3.7 mg/kg and 76% for 11 mg/kg). [2] |
Kinase Assay | In vitro mTOR kinase assays : The reaction mixture consisted of the following components in 10 μL assay buffer (50 mM Hepes pH 7.5, 10 mM MgCl 2, 3 mM MnCl 2, 1 mM EGTA, 2 mM DTT, 0.01%Tween-20): 0.10 μg/mL of in-house generated mTOR enzyme, 0.05 μM ULight-eIF4E-binding protein 1 (Thr37/46) peptide and 10 μM ATP. The mixture is incubated for 60 min at room temperature. 10 μL of Detection mixture consisted of 16 mM EDTA, 0.004 mM Eu-W1024-labeled Anti-Phospho-eIF4E-binding protein 1-(Thr37/46) antibody and 1X LANCE? Detection Buffer is then added and incubated for 60 min. |
Cell Research | CellTiter-Glo assay(Only for Reference) |
Synonyms | SB2343, VS 5584, VS5584 |
Molecular Weight | 354.41 |
Formula | C17H22N8O |
CAS No. | 1246560-33-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 3 mg/mL (8.46 mM)
DMSO: 66 mg/mL (186.2 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VS-5584 1246560-33-7 PI3K/Akt/mTOR signaling PI3K mTOR Phosphoinositide 3-kinase inhibit SB2343 SB-2343 Inhibitor SB 2343 VS 5584 VS5584 Mammalian target of Rapamycin inhibitor